Trial Profile
A clinical study of Apatinib mesylate tablets combined with radiotherapy in the treatment of patients with advanced hepatocellular carcinoma (HCC)
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 04 Jun 2018
Price :
$35
*
At a glance
- Drugs Rivoceranib (Primary)
- Indications Liver cancer
- Focus Therapeutic Use
- 04 Jun 2018 New trial record